342 related articles for article (PubMed ID: 36969025)
1. Strategies to target the cancer driver MYC in tumor cells.
Weber LI; Hartl M
Front Oncol; 2023; 13():1142111. PubMed ID: 36969025
[TBL] [Abstract][Full Text] [Related]
2. The Quest for Targets Executing MYC-Dependent Cell Transformation.
Hartl M
Front Oncol; 2016; 6():132. PubMed ID: 27313991
[TBL] [Abstract][Full Text] [Related]
3. The Diarylheptanoid Curcumin Induces MYC Inhibition and Cross-Links This Oncoprotein to the Coactivator TRRAP.
Mödlhammer A; Pfurtscheller S; Feichtner A; Hartl M; Schneider R
Front Oncol; 2021; 11():660481. PubMed ID: 33937075
[TBL] [Abstract][Full Text] [Related]
4. Strategically targeting MYC in cancer.
Posternak V; Cole MD
F1000Res; 2016; 5():. PubMed ID: 27081479
[TBL] [Abstract][Full Text] [Related]
5. MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer.
Stefan E; Bister K
Curr Top Microbiol Immunol; 2017; 407():117-151. PubMed ID: 28466200
[TBL] [Abstract][Full Text] [Related]
6. The master regulators Myc and p53 cellular signaling and functions in polycystic kidney disease.
Kurbegovic A; Trudel M
Cell Signal; 2020 Jul; 71():109594. PubMed ID: 32145315
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic protein flexibility in regulation of cell proliferation: advantages for signaling and opportunities for novel therapeutics.
Follis AV; Galea CA; Kriwacki RW
Adv Exp Med Biol; 2012; 725():27-49. PubMed ID: 22399317
[TBL] [Abstract][Full Text] [Related]
8. The brain acid-soluble protein 1 (BASP1) interferes with the oncogenic capacity of MYC and its binding to calmodulin.
Hartl M; Puglisi K; Nist A; Raffeiner P; Bister K
Mol Oncol; 2020 Mar; 14(3):625-644. PubMed ID: 31944520
[TBL] [Abstract][Full Text] [Related]
9. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
[No Abstract] [Full Text] [Related]
10. Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
Matsushita K; Shimada H; Ueda Y; Inoue M; Hasegawa M; Tomonaga T; Matsubara H; Nomura F
World J Gastroenterol; 2014 Apr; 20(15):4316-28. PubMed ID: 24764668
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional control of DNA replication licensing by Myc.
Valovka T; Schönfeld M; Raffeiner P; Breuker K; Dunzendorfer-Matt T; Hartl M; Bister K
Sci Rep; 2013 Dec; 3():3444. PubMed ID: 24309437
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity.
Li H; Fang Y; Niu C; Cao H; Mi T; Zhu H; Yuan J; Zhu J
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):E9317-E9324. PubMed ID: 30181285
[TBL] [Abstract][Full Text] [Related]
13. Interaction between the BAG1S isoform and HSP70 mediates the stability of anti-apoptotic proteins and the survival of osteosarcoma cells expressing oncogenic MYC.
Gennaro VJ; Wedegaertner H; McMahon SB
BMC Cancer; 2019 Mar; 19(1):258. PubMed ID: 30902071
[TBL] [Abstract][Full Text] [Related]
14. The Myc oncoprotein as a therapeutic target for human cancer.
Vita M; Henriksson M
Semin Cancer Biol; 2006 Aug; 16(4):318-30. PubMed ID: 16934487
[TBL] [Abstract][Full Text] [Related]
15. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
16. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.
Selvarajan V; Osato M; Nah GSS; Yan J; Chung TH; Voon DC; Ito Y; Ham MF; Salto-Tellez M; Shimizu N; Choo SN; Fan S; Chng WJ; Ng SB
Leukemia; 2017 Oct; 31(10):2219-2227. PubMed ID: 28119527
[TBL] [Abstract][Full Text] [Related]
17. Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.
Matsushita K; Tamura M; Tanaka N; Tomonaga T; Matsubara H; Shimada H; Levens D; He L; Liu J; Yoshida M; Nomura F
Mol Cancer Res; 2013 Jul; 11(7):689-98. PubMed ID: 23594796
[TBL] [Abstract][Full Text] [Related]
18. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic aspects of c-MYC signaling in inflammatory and cancerous colonic diseases.
Sipos F; Firneisz G; Műzes G
World J Gastroenterol; 2016 Sep; 22(35):7938-50. PubMed ID: 27672289
[TBL] [Abstract][Full Text] [Related]
20. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.
Menssen A; Hydbring P; Kapelle K; Vervoorts J; Diebold J; Lüscher B; Larsson LG; Hermeking H
Proc Natl Acad Sci U S A; 2012 Jan; 109(4):E187-96. PubMed ID: 22190494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
